Abstract: This invention comprising in hydroxypropyl starch for preparing empty capsules in alimentary and medical use, and hydroxypropyl starch-based soft capsules. This invention takes water as solvent, mix with propylene epoxide and catalyst for reaction, after washing, drying, hydroxypropyl starch is completed. The MS level of substitution of starch is around 2˜5, gelatinization point between 25˜60° C. After the hydroxypropyl starch is gelatinized by heating in water, a hydroxypropyl starch matrix soft capsule can be prepared. The invention consists in introducing hydroxypropyl by modifying the molecular chain of starch to improve the flexibility and hydrophilicity of starch. Therefore, a hydroxypropyl starch matrix soft capsule capable of preparing a flexible and disintegrating property is provided.

Abstract: The present disclosure relates to the technical field of building additives, and in particular to a preparation method of modified starch ether for improving the anti-sliding property of a ceramic tile adhesive. The preparation method includes chemical modification of subjecting starch to one-step etherification to obtain starch ether, followed by physical modification. In the preparation method, the cumbersome multi-step etherification in existing methods for preparing modified starch ether is avoided, and only one-step etherification is used to obtain modified starch ether of better properties. Because physical modification is added, the obtained product can significantly improve the anti-sliding property of a ceramic tile adhesive. Moreover, the conditions for one-step etherification are significantly different from the prior art.

Abstract: The invention relates to a dialysis solution having at least one osmotic agent, with the osmotic agent being a polysaccharide modified by 2-sulfoethyl groups.

Abstract: The present invention relates to glycogen-based polymers and the use thereof for enhancing the solubility in water of lipophilic compounds, to complexes of the said glycogen-based polymers with lipophilic compounds and the use thereof for administering lipophilic compounds, and to pharmaceutical, nutraceutical, and cosmetic compositions comprising the said complexes.

Abstract: Disclosed herein are methods of making high molecular weight, reduced viscosity starch pastes by enzymatic conversion. The methods provide a process for producing enzyme-thinned starch pastes that have improved molecular weight distributions, i.e., starch pastes having a more mid to high molecular weight content and less low molecular weight sugars than traditional enzyme converted pastes at similar solids and viscosity. In some embodiments, the methods utilize an enzyme capable of producing longer-chain oligosaccharides rather than low-molecular weight sugars. Other embodiments utilize a combination of enzymes to provide low viscosity pastes that are stabilized against setback and retrogradation. Furthermore, the methods may utilize a continuous starch enzyme cooker for the production of the high molecular weight, reduced viscosity starch pastes.

Abstract: Biodegradable microspheres having a diameter of 10-2000 ?m having cross-linked hydrolysed starch onto which at least one type of ligand has been coupled via a carboxylic ester bond. The ligand shall be an endogenous, charged molecule with a molecular mass of less than 1000 Da having at least one additional carboxylic acid function in addition to the one utilised for coupling the ligand to the microsphere and/or at least one amine function. On average 0.05-1.5 ligands are coupled to each glucose moiety in the hydrolysed starch.

Abstract: A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: The invention relates to a compound, comprising a) a first starch derivative selected from the group consisting of hydroxyalkyl starch, carboxyl alkyl starch, ester starch and arbitrary mixtures thereof, wherein the starch derivative has a mean relative molar mass Mw1 and a degree of molar substitution MS1, and b) a second starch derivative selected from the group consisting of hydroxyalkyl starch, carboxyl alkyl starch, ester starch and arbitrary mixtures thereof, having a mean relative molar mass Mw2 and a degree of molar substitution MS2, characterized in that Mw1 is greater than Mw2 (Mw1>Mw2) and MS2 is greater than MS1 (MS2>MS1).

Abstract: The present invention provides a modified starch, preparation method and use of the same, also provides a drilling fluid comprising the modified starch which contains bi-substituted starch structural units and tri-substituted starch structural units, wherein, the tri-substituted starch structural units are represented by the following formula (1), the bi-substituted starch structural units are the structural units represented by the following formula (2) and/or the structural units represented by the following formula (3), and the total content of the bi-substituted starch structural units and tri-substituted starch structural units accounts for 20 wt % or more of the modified starch, preferably 20-30 wt %, the weight-average molecular weight of the etherified starch is 50,000-600,000, preferably 80,000-580,000, wherein, R1, R2, and R3 are C1-C5 alkylene respectively, and M1, M2, and M3 are H, alkali metal element, or alkaline earth metal element respectively.

Abstract: A method for manufacturing a modified hydroxyethyl starch carrying a heptonic acid residue on at least one of its termini is disclosed. Within this method, the following steps are carried out: a) dissolving hydroxyethyl starch in water, b) adjusting the pH value to a value of 8.0 to 10.0, c) adding a cyanide compound to the hydroxyethyl starch solution, heating the solution to a temperature of 80 to 99° C. and keeping it at this temperature for a first time period, and d) adjusting the pH value to a value of 2.0 to 4.0, bringing the solution to a temperature of 50 to 90° C. and keeping it at this temperature for a second time period.

Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

Abstract: The present invention relates to hydroxyalkyl starch conjugates, a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent and the cytotoxic agent comprising at least one tertiary hydroxyl group, wherein the hydroxyalkyl starch is linked via said tertiary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.

Abstract: A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: The present invention relates to a method for preparing hydroxyalkyl starch. The method for preparing hydroxyalkyl starch comprises the steps of hydrolyzing starch, reducing the hydrolyzed starch, and substituting the reduced starch with hydroxyalkyl group in a dry process.

Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of head and neck cancer, especially by effectively reducing tumor growth rate and inhibiting tumor growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of cancer, tumor or tumor associated diseases, especially by effectively reducing tumor growth rate and inhibiting tumor growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of cancer, tumor or tumor associated diseases, especially by effectively reducing tumor growth rate and inhibiting tumor growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Abstract: The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

Abstract: The present invention relates to hydroxyalkyl starch conjugates, a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent and the cytotoxic agent comprising at least one tertiary hydroxyl group, wherein the hydroxyalkyl starch is linked via said tertiary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS?(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS? is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

Abstract: There are disclosed cationic crosslinked waxy starch products having a Brookfield viscosity of about 700 cps to about 2500 cps and a method for preparing the starch products. Also disclosed is the use of the cationic crosslinked waxy starch products having a Brookfield viscosity of about 700 cps to about 2500 cps in the production of paper products.

Abstract: The present invention provides for a digestive enzyme inhibitor comprising the hydrolysis products of an ?-amylase hydrolyzed hydroxypropyl substituted starch. The present invention further provides for a food or beverage ingredient composition comprising the hydrolysis products of an ?-amylase hydrolyzed hydroxypropyl substituted starch and a rapidly digestible starch, a food or beverage comprising such ingredient, and methods of use thereof, including a method of controlling postprandial glucose release after ingestion of a rapidly digestible starch.

Abstract: The present invention relates to a process for preparing a chemically modified polysaccharide, preferably starch, by using a microdevice. It further relates to the use of a microdevice for the chemical reactions of polysaccharides in heterogeneous mixtures. Examples of chemical modifications are acetylation, oxidation, hydroxypropylation and the like.

Abstract: An object of the present invention is to provide a novel starchy substance having a retrogradation-resistance, a process for producing the starchy substance efficiently from a material starch by enzymatic reaction, and uses thereof. The present invention attains the above object by providing branched starch having 6-?-maltosyl- and/or 6-?-maltotetraosyl-structure(s) with a marked retrogradation-resistance, a process for producing the branched starch without lowering the molecular weight of material starch, and uses thereof.

Abstract: An allergen inactivating agent is provided which has no adverse effects on the human body and which does not cause problems such as color development.

Abstract: The invention relates to novel transglycosylation products and their preparation. The transglycosylation products according to the invention are prepared from starch derivatives, such as esters or ethers of starch. The products are obtained by reacting a starch derivative with an alcohol in the presence of an acid catalyst. The forming product is separated by precipitation or by removing any unreacted alcohol by evaporation. In the products according to the invention the good properties of starch derivatives, such as the excellent water resistance of esters, are combined with the versatility of transglycoside products. The products can be used as adhesives, in which case they are formulated, for example as hot-melt adhesives, and as comonomers, prepolymers or macroinitiators in the preparation of polymers.

Abstract: A starch thinning and etherification process is provided comprising the steps of (a) mixing a starch substrate with a thinning agent, an alkalizing agent and an etherification agent; (b) drying the mixture of step (a); and (c) allowing the dried mixture to react with the etherification agent, wherein: the thinning agent consists of one or more hypochlorites; step (a) is carried out at an alkaline pH and does not involve any artificial heating; and step (b) is carried out before the mixture of step (a) reaches the starch substrate's gelatinisation temperature.

Abstract: The present invention relates to a preventive/remedy for obesity, which has a hydroxypropylated starch as its active ingredient. Provided are materials for foods, drugs, etc. which can exhibit an effect of preventing/lessening the onset of various lifestyle related diseases, for example, an effect of preventing/ameliorating obesity, or preventing/ameliorating hyperlipidemia; have a high safety and a wide application range; and rarely damage their texture.

Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

Abstract: A medical magnetic resonance tomography apparatus and a contrast agent for magnetic resonance tomography imaging of cavities in a patient are provided. The contrast agent is formed from a highly viscous magnetic resonance contrast agent. The highly viscous magnetic resonance contrast agent includes a substance. A specific magnetic resonance contrast can be generated by the substance.

Abstract: A molecular complex of a high molecular weight carrier substance and of a medicinal substance. The carrier substance has functional groups whereby the carrier substance and the medicinal substance are bound non-covalently. The medicinal substance is insoluble or slightly soluble in water and the carrier substance is readily soluble in water. The carrier substance can be starch or a starch derivative and can have only one functional group for non-covalent binding of the medicinal substance in each molecule.

Abstract: A process for manufacturing transglycosylation products. According to the process, a starch derivative is reacted at acidic conditions with an alkanol containing 1-6 hydroxyl groups and the reaction product is recovered as such or it is subjected to further processing. According to the method, the transglycosylation reaction between the starch derivatives and the alkanol is carried out in a reactive extrusion process, whereby the reaction can essentially be performed in the absence of liquid media at high yield. The invention also relates to new transglycosylation products of starch derivative, containing anions derived from a phosphorus-containing acid, which are chemically bonded to the product.

Abstract: A process is described for the continuous preparation and/or workup of polysaccharide derivatives by reaction and/or conditioning in a suspension with liquid reaction partners, in which, in accordance with FIG. 1, a) a preferably pumpable suspension stream of solids SE and liquid phase LE, if appropriate preheated to 185° C.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: The invention relates to compounds, comprising a conjugate of hydroxyalkyl starch (HAS) and an active agent, whereby the hydroxyalkyl starch is either directly covalently bonded to the active agent, or by means of a linker. The invention further relates to methods for the production of a covalent HAS-active agent conjugate, whereby HAS and an active agent are reacted in a reaction medium, characterised in that the reaction medium is water or a mixture of water and an organic solvent, comprising at least 10 wt. % water.

Abstract: The present invention relates to a method for the production of a viscosity regulator by introducing hydrophobic and hydrophilic groups into a starch molecule. The invention also relates to viscosity regulators produced in this manner and the use thereof. The viscosity regulators according to the invention can be used as emulsifiers or as thickening agents of surfactant-containing systems, e.g. in cosmetic or pharmaceutical preparations.

Abstract: The invention relates to an emulsifier, a method for preparing said emulsifier, and to its use in various applications, primarily food and cosmetic applications. The invention also relates to the use of said emulsifier for the creation of an elastic, gelled foam. An emulsifier according to the invention is based on a starch which is enzymatically converted, using a specific type of enzyme, and modified in a specific esterification reaction.

Abstract: Water-soluble amino acid copolymers, modified polysaccharides, acrylamide polymers, and combinations thereof, are described, for uses including flocculation of solids, particularly flocculation of soil, such as in an agricultural setting. Also described are methods of preparing selected amino acid copolymers and modified polysaccharides.

Abstract: Known hydroxyethylated and -propylated starch types for use as colloid osmotic agent in peritoneal dialysis or as volume replacement composition (plasma expander) have the disadvantage that complete degradation by amylase is not possible owing to the more or less extensive substitution by hydroxyethyl or hydroxypropyl groups. As a consequence thereof, residual fragments remain in the body and are eliminated only very slowly or are stored in various organs/tissues, especially with relatively high and/or long-term dosage. These disadvantageous properties can be very substantially avoided according to the invention with a highly branched, unsubstituted or low-substituted starch product, i.e. with a starch which has a significantly higher degree of branching than amylopectin, and has the degree of ?-I,6 branching of glycogen, or exceeds the latter and—if substituted—has a degree of substitution MS of only up to 0.3.

Abstract: New crosslinked polysaccharides useful as absorbents or superabsorbents alone or in a mixture are obtained by reacting polysaccharides (preferably containing carboxylates groups) with at least one crosslinker selected in the group constituted by activated polyethylene glycols such as for example halogenated (Cl, Br, I), mesylated, tosylated, or triflated activated polyethylene glycols.

Abstract: The present invention relates to the use of methylated starches in mineral building materials.

Abstract: The present invention is directed to a starch comprising a novel percentage of actual amylose. A grain comprising the starch is also embodied by the present invention. The present invention is also directed to a plant comprising the novel starch.

Abstract: The invention relates to a process for preparing a hydrophobic starch, comprising etherification, esterification or amidation of a root or tuber starch comprising at least 95 wt. % of amylopectin, based on dry substance of the starch, or a derivative thereof, with a substituent comprising an alkyl chain having from 4–24 carbon atoms. The invention further relates to a hydrophobic starch obtainable by said process.

Abstract: This invention relates to a starch based tablet disintegrant useful at low addition levels and providing equally effective properties in water and physiological fluids. The starches are characterized by their low solubility in cold water, high swelling power and labile birefringence in the dry state, which rapidly disappears upon addition of water. The preferred starches are inhibited then processed to remove a portion of the granular structure.

Abstract: Disclosed is a method for preparing a hydroxyalkyl starch. In accordance with the disclosed invention, the method comprises reacting the starch with a starch hydroxylating agent in the presence of an alcohol and an alcohol-soluble alkali metal, at a temperature effective to provide a cold water soluble starch, preferably at a temperature of between about 90° and about 110° C. The starch thus produced will be granular and cold water soluble.

Abstract: The present invention describes a class of new regioselectively reticulated polysaccharides. A process to obtain these polysaccharides, starting from naturally occurring, possibly substituted polysaccharides, is also described. The products can be used in the medical filed and in other industrial sectors.

Abstract: This invention relates to a starch based tablet disintegrant useful at low addition levels and providing equally effective properties in water and physiological fluids. The starches are characterized by their low solubility in cold water, high swelling power and labile birefringence in the dry state, which rapidly disappears upon addition of water. The preferred starches are inhibited then processed to remove a portion of the granular structure.

Abstract: The invention relates to a highly substituted carboxyalkyl starch which is obtained by a special slurry method. A conversion of starch with halogenated acids is thereby effected in an organic-aqueous reaction medium in the presence of alkali hydroxide. This starch is used in the chemical industry field.

Abstract: A process is described for the continuous preparation and/or workup of polysaccharide derivatives by reaction and/or conditioning in a suspension with liquid reaction partners, in which, in accordance with FIG.